Advanced search
Publication Cover
Leukemia & Lymphoma Volume 53, 2012 - Issue 8
Submit an article Journal homepage
617
Views
64
CrossRef citations to date
0
Altmetric
Research Article

Survival trends in mantle cell lymphoma in the United States over 16 years 1992–2007

Rekha ChandranLegacy Health System, Vancouver, WA, USACorrespondence[email protected]
,
Stuart K. GardinerDevers Eye Institute, Legacy Health System, Portland, OR, USA
,
Miklos SimonNorthwest Cancer Specialists, Vancouver, WA, USA
&
Stephen E. SpurgeonKnight Cancer Institute, Oregon Health Sciences University, Portland, OR, USA
Pages 1488-1493 | Received 14 Oct 2011, Accepted 08 Jan 2012, Published online: 13 Feb 2012

References

  • Onciu M, Schlette E, Medeiros LJ, . Cytogenetic findings in mantle cell lymphoma cases with a high level of peripheral blood involvement have a distinct pattern of abnormalities. Am J Clin Pathol 2001;116:886–892.
  • Banks PM, Chan J, Cleary ML, . Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol 1992;16:637–640.
  • Harris NL, Jaffe ES, Stein H, . A revised European-American classification of lymphoid neoplasms: a proposal from the international lymphoma study group. Blood 1994;84:1361–1392.
  • Zhou Y, Wang H, Fang W, . Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 2008;113:791–798.
  • Decaudin D, Bosq J, Tertian G, . Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas. J Clin Oncol 1998;16:579–583.
  • Foran JM, Rohatiner AZ, Coiffier B, . Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma. J Clin Oncol 1999;17:546–553.
  • de Guibert S, Jaccard A, Bernard M, . Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma. Haematologica 2006; 91:425–426.
  • Romaguera JE, Fayad L, Rodriguez MA, . High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013–7023.
  • Geisler CH, Kolstad A, Laurell A, . Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008;112:2687–2693.
  • Herrmann A, Hoster E, Zwingers T, . Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009;27:511–518.
  • Schmidt C, Dreyling M. Therapy of mantle cell lymphoma: current standards and future strategies. Hematol Oncol Clin North Am 2008;22:953–963, ix.
  • Leitch HA, Gascoyne RD, Chhanabhai M, . Limited-stage mantle-cell lymphoma. Ann Oncol 2003;14:1555–1561.
  • Rummel MJ, Chow KU, Karakas T, . Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma. Eur J Cancer 2002;38: 1739–1746.
  • Howard OM, Gribben JG, Neuberg DS, . Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002;20:1288–1294.
  • Epner EM, Unger J, Miller T. A multi center trial of hyper CVAD + rituxan in patients with newly diagnosed cell lymphoma. Blood 2007;110(Suppl. 1): Abstract 387.
  • SEER Research Data 1973 - 2007: Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1973 - 2007), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2010, based on the November 2009 submission. [Internet]. Available from: www.seer.cancer.gov
  • Andersen NS, Jensen MK, de Nully Brown P, . A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors. Eur J Cancer 2002;38:401–408.
  • Velders GA, Kluin-Nelemans JC, De Boer CJ, . Mantle-cell lymphoma: a population-based clinical study. J Clin Oncol 1996;14: 1269–1274.
  • Riihijarvi S, Taskinen M, Jerkeman M, . Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy. Eur J Haematol 2011;86:124–128.
  • Pal SK, Hurria A. Impact of age, sex, and comorbidity on cancer therapy and disease progression. J Clin Oncol 2010;28:4086–4093.
  • Clarke CA, Undurraga DM, Harasty PJ, . Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. Cancer Epidemiol Biomarkers Prev 2006;15:630–638.
  • Zhou Y, Zhang L, Romaguera J, . Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond. Am J Hematol 2008;83:144–149.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.